Hanzhong Li

Hanzhong Li

Company: Eureka Therapeutics

Job title: SVP, Corporate Development


Towards Safer, Effective and Persistent T-Cell Therapies: Development of Antibody-TCR (AbTCR) Expressing T Cells Against Solid and Hematological Malignancies 12:45 pm

Addressing major barriers of current CAR-T: CRS and neurotoxicity risks Presenting our solution: ARTEMIS AbTCR T-cell Receptor Platform Safety validation of ARTEMIS platform in CD19+ NHL Understanding how Eureka built a versatile structure to go after both haem and solid tumor with ARTEMIS Plus Safety and efficacy validation in AFP+ HCC and CD19 programs are…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.